Sunday, October 18, 2009
55 - Drugs causing Megaloblastic anemia
2. Primidone (anticonvulsant)
3. Phenobarbitone (anticonvulsant)
4. Sulfasalazine
5. Nitrous oxide
6. Folate antagonists (inhibitors of Dihydrofolate reductase) like Methotrexate, Pentamidine, Pyrimethamine, Triamterene, Trimethoprim and Cotrimoxazole.
7. Drugs that inhibit DNA synthesis may cause Megaloblastic anemia
example : 6a. Purine antagonists = 6-Mercaptopurine, Azathioprine.
6b. Pyramidine antagonists = 5 FU, Cytosine arabinoside .
6c. Others = Hydroxyurea, acyclovir and zidovudine (AZT, Azidothymidine).
8. Nitrofurantoin (less well documented)
9. Tetracycline (less well documented)
10. Anti-Tuberculosis drugs (less well documented)
Thursday, October 15, 2009
54 - Monoclonal antibodies approved for Hematological and Solid tumors
ANTIGEN AND TUMOR CELL TARGETS | ANTIGEN FUNCTION | NAKED ANTIBODIES |
---|---|---|
Antigen: CD20 | Proliferation/differentiation | Rituximab (chimeric) |
Tumor type: B-cell lymphoma and CLL | ||
Antigen: CD52 | Unknown | Alemtuzumab (humanized) |
Tumor type: B-cell CLL and T-cell lymphoma | ||
Antigen: CD25 alpha subunit | Activation antigen | Daclizumab (humanized) |
Tumor type: T-cell mycosis fungoides | ||
Antigen: CD33 | Unknown | Gemtuzumab (humanized) |
Tumor type: acute myeloid leukemia | ||
Antigen: HER2/neu (ErbB-2) | Tyrosine kinase | Trastuzumab (humanized) |
Tumor type: breast cancer | ||
Antigen: EGFR (ErbB-1) | Tyrosine kinase | Cetuximab (chimeric) |
Tumor type: colorectal; NSCLC; pancreatic, breast | ||
Antigen: VEGF | Angiogenesis | Bevacizumab (humanized) |
Tumor type: colorectal cancer |
Sunday, September 20, 2009
53 - Benzodiazepine interactions with other drugs
| ||||||||||||||||||||||
|
Monday, September 14, 2009
52 - Drugs causing Fatty liver
2. Antibiotic - Tetracycline ( high-dose, intravenous )
3. Anticonvulsant - Valproic acid
4. Antiviral - Dideoxynucleosides ( eg: Zidovudine ), protease inhibitors ( indinavir, ritonavir )
5. Oncotherapeutics - Asparginase, Methotrexate .
Friday, September 11, 2009
51 - Antimicrobial chemotherapy - Rest of drugs
Inhibitors of nucleic acid synthesis | Quinolones | DNA gyrase | Bactericidal |
Novobiocin | DNA gyrase | Bacteriostatic | |
Flucytosine | Fungal thymidylate synthetase | Fungicidal | |
Rifampin | DNA-dependent RNA polymerase | Bactericidal | |
Inhibitors of folate metabolism | Sulfonamides | Pteroic acid synthetase | Bacteriostatic |
Trimethoprim | Dihydrofolate reductase | Bacteriostatic | |
Inhibitor of mycolic acid synthesis | Isoniazid | Mycobacterial mycolic acid biosynthesis | Bactericidal |
Alteration of cytoplasmic membrane | Polymyxins | Bacterial membrane permeability | Bactericidal |
Polyenes | Fungal membrane permeability | Fungicidal | |
Azoles | Fungal ergosterol biosynthesis | Fungicidal |
50 - Antimicrobial chemotherapy - Protein biosynthesis inhibitors
Streptomycin | 30S ribosomal subunit | Bactericidal |
Gentamicin | 30S ribosomal subunit | Bactericidal |
Tetracycline | 30S ribosomal subunit | Bacteriostatic |
Spectinomycin | 30S ribosomal subunit | Bacteriostatic |
Chloramphenicol | 50S ribosomal subunit | Bacteriostatic |
Erythromycin | 50S ribosomal subunit | Bacteriostatic |
Clindamycin | 50S ribosomal subunit | Bacteriostatic |
Griseofulvin | Microtubule function | Fungistatic |
49 - Antimicrobial chemotherapy - Cell wall synthesis inhibitors
| AGENT Cycloserine | SITE OF ACTION Peptidoglycan tetrapeptide side chain | EFFECT Bactericidal | |
Phosphomycin | Formation of N-acetylmuramic acid | Bactericidal | ||
Bacitracin | Membrane carrier molecule | Bactericidal | ||
Penicillins | Peptidoglycan cross-linking | Bactericidal | ||
Cephalosporins carbapenems | , Peptidoglycan cross-linking | Bactericidal | ||
Vancomycin | Translocation of cell wall intermediates | Bactericidal |
48 - Atypical Antipsychotic drugs
1. Risperidone
2. Quetiapine
3. Arisipiprazole
4. Clozapine
5. Olanzapine
6. Ziprasodine
Click here to read the mnemonic used to remember these drugs .
Sunday, August 23, 2009
47 - Drugs causing Parkinsonism
1. Fluoxetine
2. Valproate
3. Alpha methyl dopa
4. Neuroleptics
5. Dopamine depleting agents
6. Anti-emetics
7. Lithium carbonate
8. Some selective anti-psychotics
Toxins which cause parkinsonism are :
1. CO ( carbonmonoxide )
2. Cyanide
3. CS2
4. Manganese
5. Methanol
6. MPTP
7. N-Hexane
Friday, May 22, 2009
46 - Molecularly targeted anticancer drugs
1. imatinib
2. tretinoin
3. bexarotene
4. gemtuzumab ozogamicin
5. denileukin diftitox
6. gefitinib
7. erlotinib
8. dasatinib
9. sorafenib
10. sunitinib
45 - Antimitotic agents ( Anticancer drugs )
1. vincristine
2. vinblastine
3. vinorelbine
4. paclitaxel
5. docetaxel
6. etramustine phosphate
7. NAB-paclitaxel ( protein bound )
44 - Antimetabolites drugs ( Anticancer drugs )
1. deoxycoformycin (pentostatin) ^
2. 6-mercaptopurine ^
3. 6-thioguanine ^
4. azathioprine ^
5. 2-chlorodeoxy adenosine (cladribine) ^
6. fludarabine phosphate ^
7. asparaginase
8. hydroxy urea
9. capacitabine "
10. cytosine arabinoside "
11. azacytidine "
12. gemcitabine "
13. 5-fluorouracil "
14. methotrexate ~
15. pemetrexed ~
---------------------------------
^ (1-6) Purine analogs and related inhibitors .
" (9-13) Pyramidine analogs
~ (14,15) Folic acid analogs
43 - Antitumor antibiotics ( Anticancer agents )
1. bleomycin
2. actinomycin D
3. mitomycin C
4. etoposide ( VP16-213 )
5. topotecan
6. irinotecan ( CPT II )
7. doxorubicin and daunorubicin
8. idarubicin
9. epirubicin
10. mitoxantrone
42 - Alkylating agents ( Anticancer drugs )
1. cyclophosphamide*
2. mechlorethamine*
3. chlorambucil*
4. melphalan(L-sarcolysin)*
5. ifosfamide*
6. lomustine ( CCNU ) %
7. carmustine ( BCNU ) %
8. streptozocin (streptozotocin) %
9. dacarbazine ( DTIC; dimethyltriazenoimidazole carboxamide ) =
10. temozolomide =
11. oxaliplatin -
12. cisplatin -
13. carboplatin -
14. altretamine ( formerly hexamethyl melamine ) +
15. thiotepa +
16. procarbazine (N-methyl hydrazine, MIH) !
17. busulfan $
-----------------------------
* (1-5) Nitrogen mustards
% (6-8) Nitrosoureas
= (9,10) Triazenes
- (11-13) Platinum coordination complexes
+ (14,15) Ethyleneimines and methylmelamines
! (16) Methylhydrazine derivative
$ (17) Alkyl sulfonate
Tuesday, April 7, 2009
41 - Drugs Causing Pseudotumor cerebri
2. Oral contraceptives
3. Tetracyclines
4. Glucocorticoids ( withdrawal )
5. Amiodarone
6. Mineralocorticoids ( withdrawal )
I always use a funny mnemonic for this - HOT GLUCOSE AND MINERALS - cause pseudotumor
cerebri . use it if u like it or make your own one . click here if u wanna read more such mnemonics .
Thursday, April 2, 2009
40 - Drugs causing pancreatitis
1. 5-Aminosalicylate
2. 6-Mercaptopurine
3. Azathioprine
4. Cytosine arabinoside
5. Dideoxyinosine
6. Diuretics
7. Estrogens
8. Furosemide
9. Metronidazole
10. Pentamidine
11. Tetracycline
12. Thiazide
13. Trimethoprim-sulfamethoxazole
14. Valproic acid
Probable Cause :
1. Acetaminophen
2. α-Methyl-DOPA
3. Isoniazid
4. l-Asparaginase
5. Phenformin
6. Procainamide
7. Sulindac
Wednesday, April 1, 2009
39 - Drugs causing myopathy
- lipid lowering agents :
1a. fibric acid derivatives
1b. HMG CoA reductase inhibitors ( statins )
1c. niacin ( nicotinic acid derivatives )
- glucocorticoids
- zidovudine
- Non depolarizing neuromuscular blocking agents
- drugs of abuse :
5a. alcohol
5b. amphetamines
5c. cocaine
5d. heroin
5e. phencyclidine
5f. meperidine
- autoimmune toxic myopathy : D – pencillamine
- amphophilic cationic drugs :
7a. amiodarone
7b. chloroquine
7c. hydroxychloroquine
- antimicrotubular drugs : colchicine
- miscellaneous drugs :
9a. cyclosporine
9b. cimetidine
9c. gold
9d. danazol
9e. amphotericin – B
Saturday, March 14, 2009
38 - glucose 6 phosphate dehydrogenase deficiency - hemolysis causing drugs
1. all of the following drugs cause definite hemolysis in a glucose-6-phosphate dehydrogenase deficient patient except ?
a. primaquine
b. nitrofurantoin
c. naphthalene
d. ciprofloxacin
answer: d . ciprofloxacin .
u have to memorise the following drugs to answer questions related to this topic.
Drugs which carry a definite risk of hemolysis in a patient with glucose-6-phosphate dehydrogenase deficiency :
1. antimalarials : primaquine, dapsone/chlorproguanil
2. sulphonamides/sulphones : sulphamethoxazole and others, dapsone
3. antibacterial/antibiotics : cotrimoxazole, nalidixic acid, nitrofurantoin, niridazole
4. antipyretic/analgesics : acetanilide, phenazopyridine (pyridium)
5. other drugs : naphthalene, methylene blue
Drugs which carry a possible risk of hemolysis in a patient with glucose-6-phosphate dehydrogenase deficiency :
1. antimalarials : chloroquine
2. sulphonamides : sulfasalazine, sulfadimidine
3. antibacterials/antibiotics : ciprofloxacin, norfloxacin
4. antipyretic/analgesics : acetylsalicylic acid high dose ( greater than 3 g/d )
5. other drugs : vitamin K analogues, ascorbic acid greater than 1 gram and rasburicase
Drugs which carry a doubtful risk of hemolysis in a patient with glucose-6-phosphate dehydrogenase deficiency :
1. antimalarials : quinine
2. sulphonamides/sulphones : sulfisoxazole, sulfadiazine
3. antibacterial/antibiotics : chloramphenicol, p-aminosalicylic acid
4. antipyretic/analgesics : acetyl salicylic acid less than 3 g/d, acetaminophen, phenacetin
5. other drugs : doxorubicin, probenecid .
Sunday, January 11, 2009
37 - pharmacology mcqs - 58 to 68
36 - pharmacology mcqs - 47 to 57
35 - P450 microsomal enzyme inducers and inhibitors
34 - pharmacology mcqs - 36 to 46
33 - finasteride mcqs
Finasteride (marketed as Proscar, Propecia, Fincar, Finpecia, Finax, Finast, Finara, Finalo, Prosteride, Gefina, Appecia,Finasterid IVAX, Finasterid Alternova) is a synthetic antiandrogen which acts by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, andprostate cancer in higher doses. A May, 2008 study indicates that Finasteride reduces the rate of prostate cancer by 30% . It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. Additionally, it is registered in many countries for androgenetic alopecia (male-pattern baldness).
Finasteride was approved initially in 1992 as Proscar, a treatment for prostate enlargement, but the sponsor had studied 1 mg of finasteride and demonstrated hair growth in male pattern hair loss. On December 22, 1997, the